The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
| Autor: | Adrian Wagg, Danny Ulahannan |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Drug
Male medicine.medical_specialty Tolterodine Tartrate media_common.quotation_subject Phenylpropanolamine Urology Severe disease Muscarinic Antagonists Review Placebo Pharmacological treatment Cresols Internal medicine Medicine Humans Benzhydryl Compounds media_common Aged urgency incontinence Aged 80 and over business.industry Urinary Bladder Overactive RC952-954.6 General Medicine Middle Aged medicine.disease tolterodine Overactive bladder Tolerability Geriatrics Delayed-Action Preparations Female overactive bladder Tolterodine Geriatrics and Gerontology Extended release business medicine.drug |
| Zdroj: | Clinical Interventions in Aging Clinical Interventions in Aging, Vol Volume 4, Pp 191-196 (2009) |
| ISSN: | 1178-1998 |
| Popis: | Danny Ulahannan, Adrian WaggDepartment of Geriatric Medicine, University College Hospital, London, UKAbstract: After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies.Keywords: overactive bladder, tolterodine, urgency incontinence |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|